Connection

Search Results to Matthew Kulke, MD

This is a "connection" page, showing the details of why an item matched the keywords from your search.

                     
                     

One or more keywords matched the following properties of Kulke, Matthew

PropertyValue
Research Expertise & Professional Interests Matthew Kulke MD is the Chief of Hematology/Oncology, Co-Director of the BU/BMC Cancer Center and Zoltan Kohn Professor at the Boston University School of Medicine. Dr. Kulke is an internationally recognized for his work in the field of neuroendocrine tumors. He has led or co-led both early and late stage clinical trials leading to the development of telotristat ethyl, temozolomide, sunitinib, everolimus and peptide receptor radiotherapy for the treatment of neuroendocrine tumors. His work has additionally included characterization of neuroendocrine tumors at the molecular level, and has resulted in over 200 peer-reviewed publications. Dr. Kulke received his undergraduate degree in molecular biology from Princeton University magna cum laude, and his medical degree with a thesis honors award from the University of California, San Francisco School of Medicine where he also was a Regent’s scholar and received a research training fellowship from the Howard Hughes Medical Institute. He performed his internship and residency at Brigham and Women’s Hospital, a medical oncology fellowship at Dana-Farber Cancer Institute, and received a Masters in Medical Science Degree from Harvard Medical School. Prior to coming to Boston University he was a Professor of Medicine at Harvard Medical School and Director of the Neuroendocrine Tumor Program at Dana-Farber Cancer Institute. He has served as principal investigator for NCI cooperative group trials in both neuroendocrine tumors and pancreatic cancer, served as chair of the National Cancer Institute’s Neuroendocrine Tumor Clinical Trial Task Force, chair of the North American Neuroendocrine Tumor Society, and chair of the National Comprehensive Cancer Network’s neuroendocrine tumor guidelines committee.

One or more keywords matched the following items that are connected to Kulke, Matthew

Item TypeName
Concept Pancreatic Neoplasms
Academic Article Sequencing and combining systemic therapies for pancreatic neuroendocrine tumors.
Academic Article Determination of an optimal response cut-off able to predict progression-free survival in patients with well-differentiated advanced pancreatic neuroendocrine tumours treated with sunitinib: an alternative to the current RECIST-defined response.
Academic Article Lack of efficacy of streptozocin and doxorubicin in patients with advanced pancreatic endocrine tumors.
Academic Article Defining molecular classifications and targets in gastroenteropancreatic neuroendocrine tumors through DNA microarray analysis.
Academic Article Recent developments in the pharmacological treatment of advanced pancreatic cancer.
Academic Article Systemic therapy for advanced pancreatic neuroendocrine tumors.
Academic Article Neuroendocrine tumours: clinical presentation and management of localized disease.
Academic Article Hoxc6 is overexpressed in gastrointestinal carcinoids and interacts with JunD to regulate tumor growth.
Academic Article Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas.
Academic Article Advances in the treatment of neuroendocrine tumors.
Academic Article Drug-related pneumonitis during mammalian target of rapamycin inhibitor therapy in patients with neuroendocrine tumors: a radiographic pattern-based approach.
Academic Article NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas.
Academic Article Alkaline phosphatase predicts survival in patients with metastatic neuroendocrine tumors.
Academic Article Medical Management of Pancreatic Neuroendocrine Tumors: Current and Future Therapy.
Academic Article Chromogranin A and neuron-specific enolase as prognostic markers in patients with advanced pNET treated with everolimus.
Academic Article Three new pancreatic cancer susceptibility signals identified on chromosomes 1q32.1, 5p15.33 and 8q24.21.
Academic Article Metastatic pancreatic cancer.
Academic Article Combination chemotherapy for advanced pancreatic cancer--has its time finally come?
Academic Article A Phase II Study of BEZ235 in Patients with Everolimus-resistant, Advanced Pancreatic Neuroendocrine Tumours.
Academic Article Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer.
Academic Article Evolving diagnostic and treatment strategies for pancreatic neuroendocrine tumors.
Academic Article Genetic associations with neuroendocrine tumor risk: results from a genome-wide association study.
Academic Article Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors.
Academic Article Genome-wide association study identifies multiple susceptibility loci for pancreatic cancer.
Academic Article DNA repair enzyme expression and differential response to temozolomide in a patient with both glioblastoma and metastatic pancreatic neuroendocrine tumor.
Academic Article Survival among patients with pancreatic cancer and long-standing or recent-onset diabetes mellitus.
Academic Article A multi-institutional, phase II open-label study of ganitumab (AMG 479) in advanced carcinoid and pancreatic neuroendocrine tumors.
Academic Article A prospective, phase 1/2 study of everolimus and temozolomide in patients with advanced pancreatic neuroendocrine tumor.
Academic Article Management of pancreatic neuroendocrine tumors.
Academic Article Progress in the treatment of neuroendocrine tumors.
Academic Article Glycemic control in patients with insulinoma treated with everolimus.
Academic Article Pazopanib and depot octreotide in advanced, well-differentiated neuroendocrine tumours: a multicentre, single-group, phase 2 study.
Academic Article A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial.
Academic Article Activity of sunitinib in patients with advanced neuroendocrine tumors.
Academic Article Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine.
Academic Article Plasma inflammatory cytokines and survival of pancreatic cancer patients.
Academic Article Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904.
Academic Article Development of a Framework Based on Reflective MCDA to Support Patient-Clinician Shared Decision-Making: The Case of the Management of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) in the United States.
Academic Article A Phase II study of gemcitabine and docetaxel in patients with metastatic pancreatic carcinoma.
Academic Article A tale of two tumors: treating pancreatic and extrapancreatic neuroendocrine tumors.
Academic Article Urinary TIMP-1 and MMP-2 levels detect the presence of pancreatic malignancies.
Academic Article Novel Treatment Options for Neuroendocrine Tumors.
Academic Article Genome-wide meta-analysis identifies five new susceptibility loci for pancreatic cancer.
Academic Article Advanced pancreatic cancer: is there a role for combination therapy?
Academic Article O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors.
Academic Article Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial.
Academic Article Neuroendocrine tumors: answers-and questions.
Award or Honor Receipt Ruth Brufsky Award for Excellence in Clinical Research on Pancreatic Cancer Research
Academic Article Altered exocrine function can drive adipose wasting in early pancreatic cancer.
Academic Article Efficacy and Safety of Sunitinib in Patients with Well-Differentiated Pancreatic Neuroendocrine Tumours.
Academic Article Guidance on 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy from the Experience of a Single Nuclear Medicine Division.
Academic Article Treatment Outcomes in Patients with Metastatic Neuroendocrine Tumors: a Retrospective Analysis of a Community Oncology Database.
Academic Article Characterization of the Neuroendocrine Tumor Immune Microenvironment.
Academic Article Pharmacogenomic analyses of sunitinib in patients with pancreatic neuroendocrine tumors.
Academic Article Enhancer signatures stratify and predict outcomes of non-functional pancreatic neuroendocrine tumors.
Academic Article Postdiagnosis Loss of Skeletal Muscle, but Not Adipose Tissue, Is Associated with Shorter Survival of Patients with Advanced Pancreatic Cancer.

Highlights
Search Criteria
  • Pancreatic Cancer